Sirtex Medical Limited is a medical device company, providing radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany, and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex delisted from the Australian Securities Exchange (ASX:SRX) on Monday, September 24, 2018.
The company is currently headed by Kevin R. Smith, who was appointed as CEO on October 16, 2019.
SIR-Spheres & microspheres mechanisms
When SIR-Spheres microspheres are used to treat liver cancer, the treatment is called selective internal radiation therapy (called SIRT). This is a relatively new treatment option for people suffering from inoperable liver cancer. SIR-Spheres are very small radioactive beads about one third the size of a human hair width that are injected into tumors within the liver.
Medical uses
The radioactive microspheres have a half-life of about 64 hours. They are administered by a trained interventional radiologist who specializes in minimally invasive, targeted treatments. The procedure is usually performed under local sedation. A small incision is made in the patient's groin and a flexible catheter is guided into the liver through the femoral artery in the leg up to the tumor sites. The catheter is moved through the hepatic artery and positioned by the interventional radiologist to allow for targeted infusion of the SIR-Spheres microspheres to the site of the tumors. The microspheres take approximately 15 minutes to be infused, the whole procedure taking about one hour. Most patients are discharged within 24 hours.
Cancers treated
Primary liver cancer
Primary liver cancer, or hepatocellular carcinoma (HCC) is the most common form of liver cancer, responsible for about 90% of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year. This comprises approximately 19,000 in the US, 54,000 in Europe and 390,000 in China, Korea, and Japan. The incidence of HCC is increasing due to increased rates of chronic infection with Hepatitis B and Hepatitis C in Asia. Other risk factors include iron overload, alcoholic cirrhosis and some congenital disorders. Five-year survival rates for liver cancer patients are low relative to other cancers.
Metastatic colorectal cancer
Colorectal cancer (CRC), also called colon cancer or large bowel cancer, is the third leading cause of cancer-related death in the western world. An estimated 1.6 million people are diagnosed with the disease worldwide every year. An estimated 50% of CRC patients will show liver metastases. It is this form of metastatic colorectal cancer (mCRC) Sirtex targets with SIR-Spheres microspheres. It has been estimated that in 30-40% of patients with advanced disease, the liver is the only site of spread.
At presentation, 20-25% of patients will have clinically detectable liver metastases and up to 50% of all patients will develop liver metastases after re-section of the primary tumor within three years of follow up. Of those patients with metastatic liver disease, approximately 25% (on average) are eligible for liver re-section surgery, which represents the only potential cure available to patients. The remainder are eligible for alternative forms of treatment, namely chemotherapy and other technologies, including SIR-Spheres microspheres.
Research and development
Sirtex is currently looking at new ways to treat other forms of cancer using the SIR-Spheres technology. This research is taking place at the Australian National University (ANU) and several institutions in the US and Europe. Sirtex is also working to develop a new technology that will help improve the treatment and survival of cancer patients. At present this is focused on the three areas listed below.